Cogentech S.R.L. Società Benefit a Socio Unico soggetta all’attività di direzione e coordinamento di IFOM - Istituto Fondazione di Oncologia Molecolare ETS (Italy)
Valeria Pensotti
Via Adamello 16
Milan
https://www.cogentech.it/diagnostic-services-overview.php
RRID: RRID:SCR_026940
1.) Tibiletti MG, Carnevali I, Facchi S, Pensotti V, Formenti G, Sahnane N, Libera L, Ronchi S, Volorio S, Pierotti MA, La Rosa S, Sessa F (2025 Jul 1). From Therapy to Cancer Prevention Using HRD Testing on Patients with High-grade Ovarian Cancer. Cancer prevention research (Philadelphia, Pa.), 18(7), 393-400. doi: 10.1158/1940-6207.CAPR-24-0474. PMID: 40244633.
2.) Brignola C, Volorio S, De Vecchi G, Zaffaroni D, Dall'Olio V, Mariette F, Sardella D, Capra F, Signoroni S, Rausa E, Vitellaro M, Pensotti V, Ricci MT (2024 Feb). De novo germline pathogenic variant in Lynch Syndrome: A rare event or the tip of the iceberg? Tumori, 110(1), 69-73. . PMID: 37691472.
3.) Varinelli L, Guaglio M, Brich S, Zanutto S, Belfiore A, Zanardi F, Iannelli F, Oldani A, Costa E, Chighizola M, Lorenc E, Minardi SP, Fortuzzi S, Filugelli M, Garzone G, Pisati F, Vecchi M, Pruneri G, Kusamura S, Baratti D, Cattaneo L, Parazzoli D, Podestà A, Milione M, Deraco M, Pierotti MA, Gariboldi M (2023 Apr 6). Decellularized extracellular matrix as scaffold for cancer organoid cultures of colorectal peritoneal metastases. Journal of molecular cell biology, 14(11), . . PMID: 36460033.
4.) Maragliano R, Libera L, Carnevali I, Pensotti V, De Vecchi G, Testa M, Amaglio C, Leoni E, Formenti G, Sessa F, Furlan D, Uccella S (2022 Sep). Mixed Neuroendocrine/Non-neuroendocrine Neoplasm (MiNEN) of the Ovary Arising from Endometriosis: Molecular Pathology Analysis in Support of a Pathogenetic Paradigm. Endocrine pathology, 33(3), 400-410. . PMID: 34342838.
5.) Tibiletti MG, Carnevali I, Pensotti V, Chiaravalli AM, Facchi S, Volorio S, Mariette F, Mariani P, Fortuzzi S, Pierotti MA, Sessa F (2022 May 23). OncoPan(®): An NGS-Based Screening Methodology to Identify Molecular Markers for Therapy and Risk Assessment in Pancreatic Ductal Adenocarcinoma. Biomedicines, 10(5), . . PMID: 35625944.
6.) Zanutto S, Ciniselli CM, Belfiore A, Dall'Olio V, Tizzoni L, Varinelli L, Pierotti MA, Battaglia L, Verderio P, Guaglio M, Gariboldi M (2022 Mar). Exploring the association with disease recurrence of miRNAs predictive of colorectal cancer. The International journal of biological markers, 37(1), 102-109. doi: 10.1177/17246008211064915. PMID: 34931559.
7.) Carnevali I, Tedaldi G, Pensotti V, Sahnane N, Micello D, Rovera F, Sessa F, Tibiletti MG (2022). Case Report: Male Lobular Breast Cancer in Hereditary Cancer Syndromes. Frontiers in oncology, 12(), 891426. . PMID: 35686104.
8.) Azzollini J, Ferrari A, Stracuzzi A, Chiaravalli S, Terenziani M, Spreafico F, Grasso M, Collini P, Pensotti V, Massimino M, Arbustini E, Manoukian S (2021 Dec). Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families. Tumori, 107(6), NP144-NP148. doi: 10.1177/03008916211058788. PMID: 34761719.
9.) Urso EDL, Ponz de Leon M, Vitellaro M, Piozzi GN, Bao QR, Martayan A, Remo A, Stigliano V, Oliani C, Lucci Cordisco E, Pucciarelli S, Ranzani GN, Viel A (2021 Apr). Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53(4), 409-417. doi: 10.1016/j.dld.2020.11.018. PMID: 33504457.
10.) Figlioli G, De Nicolo A, Catucci I, Manoukian S, Peissel B, Azzollini J, Beltrami B, Bonanni B, Calvello M, Bondavalli D, Pasini B, Vignolo Lutati F, Ogliara P, Zuradelli M, Pensotti V, De Vecchi G, Volorio S, Verderio P, Pizzamiglio S, Matullo G, Aneli S, Birolo G, Zanardi F, Tondini C, Zambelli A, Livraghi L, Franchi M, Radice P, Peterlongo P (2021 Jan 30). Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy. Cancers, 13(3), . . PMID: 33573335.
11.) Carnevali I, Di Lauro E, Pensotti V, Sahnane N, Leoni E, Formenti G, Ghezzi F, Sessa F, Tibiletti MG (2020 Dec). HPV nonrelated endocervical adenocarcinoma in hereditary cancer syndromes. Tumori, 106(6), NP67-NP72. doi: 10.1177/0300891620936752. PMID: 32635821.
12.) Azzollini J, Schiavello E, Buttarelli FR, Clerici CA, Tizzoni L, Vecchi G, Capra F, Pisati F, Biassoni V, Runza L, Carrabba G, Giangaspero F, Massimino M, Pensotti V, Manoukian S (2020 Sep 3). Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma. Cancers, 12(9), . . PMID: 32899294.
13.) Zanutto S, Ciniselli CM, Belfiore A, Lecchi M, Masci E, Delconte G, Primignani M, Tosetti G, Dal Fante M, Fazzini L, Airoldi A, Vangeli M, Turpini F, Rubis Passoni GG, Viaggi P, Arena M, Motta RIO, Cantù AM, Crosta C, De Roberto G, Iannuzzi F, Cassinotti A, Dall'Olio V, Tizzoni L, Sozzi G, Meroni E, Bisanti L, Pierotti MA, Verderio P, Gariboldi M (2020 Feb 15). Plasma miRNA-based signatures in CRC screening programs. International journal of cancer, 146(4), 1164-1173. doi: 10.1002/ijc.32573. PMID: 31304978.
14.) Ricci MT, Volorio S, Signoroni S, Mariani P, Mariette F, Sardella D, Pensotti V, Vitellaro M (2019 Aug). Development, technical validation, and clinical application of a multigene panel for hereditary gastrointestinal cancer and polyposis. Tumori, 105(4), 338-352. doi: 10.1177/0300891619847085. PMID: 31068090.
15.) Bendinelli P, Maroni P, Dall'Olio V, Matteucci E, Desiderio MA (2019 May 22). Bone Metastasis Phenotype and Growth Undergo Regulation by Micro-Environment Stimuli: Efficacy of Early Therapy with HGF or TGFβ1-Type I Receptor Blockade. International journal of molecular sciences, 20(10), . . PMID: 31121879.
16.) Gelli E, Colombo M, Pinto AM, De Vecchi G, Foglia C, Amitrano S, Morbidoni V, Imperatore V, Manoukian S, Baldassarri M, Lo Rizzo C, Catania L, Frullanti E, Tagliafico E, Cortesi L, Spaggiari F, Mencarelli MA, Trevisson E, Radice P, Renieri A, Ariani F (2019 Mar 1). Usefulness and Limitations of Comprehensive Characterization of mRNA Splicing Profiles in the Definition of the Clinical Relevance of BRCA1/2 Variants of Uncertain Significance. Cancers, 11(3), . . PMID: 30832263.
17.) Signoroni S, Tibiletti MG, Ricci MT, Milione M, Perrone F, Pensotti V, Chiaravalli AM, Carnevali I, Morabito A, Bertario L, Vitellaro M (2019 Feb). Performance of tumor testing for Lynch syndrome identification in patients with colorectal cancer: A retrospective single-center study. Tumori, 105(1), 76-83. doi: 10.1177/0300891618792460. PMID: 30117378.
18.) Colombo M, Lòpez-Perolio I, Meeks HD, Caleca L, Parsons MT, Li H, De Vecchi G, Tudini E, Foglia C, Mondini P, Manoukian S, Behar R, Garcia EBG, Meindl A, Montagna M, Niederacher D, Schmidt AY, Varesco L, Wappenschmidt B, Bolla MK, Dennis J, Michailidou K, Wang Q, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadel A, Benitez J, Boeckx B, Bogdanova NV, Bojesen SE, Bonanni B, Brauch H, Brenner H, Burwinkel B, Chang-Claude J, Conroy DM, Couch FJ, Cox A, Cross SS, Czene K, (2018 May). The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human mutation, 39(5), 729-741. . PMID: 29460995.
19.) Catucci I, Osorio A, Arver B, Neidhardt G, Bogliolo M, Zanardi F, Riboni M, Minardi S, Pujol R, Azzollini J, Peissel B, Manoukian S, De Vecchi G, Casola S, Hauke J, Richters L, Rhiem K, Schmutzler RK, Wallander K, Törngren T, Borg Å, Radice P, Surrallés J, Hahnen E, Ehrencrona H, Kvist A, Benitez J, Peterlongo P (2018 Apr). Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. Genetics in medicine : official journal of the American College of Medical Genetics, 20(4), 452-457. doi: 10.1038/gim.2017.123. PMID: 28837162.
20.) Bondavalli D, Malvestiti F, Pensotti V, Feroce I, Bonanni B (2018 Mar). BRCA1 homozygous unclassified variant in a patient with non-Fanconi anemia: A case report. Oncology letters, 15(3), 3329-3332. . PMID: 29435075.
21.) Colaluca IN, Basile A, Freiburger L, D'Uva V, Disalvatore D, Vecchi M, Confalonieri S, Tosoni D, Cecatiello V, Malabarba MG, Yang CJ, Kainosho M, Sattler M, Mapelli M, Pece S, Di Fiore PP (2018 Feb 5). A Numb-Mdm2 fuzzy complex reveals an isoform-specific involvement of Numb in breast cancer. The Journal of cell biology, 217(2), 745-762. . PMID: 29269425.
22.) Caleca L, Catucci I, Figlioli G, De Cecco L, Pesaran T, Ward M, Volorio S, Falanga A, Marchetti M, Iascone M, Tondini C, Zambelli A, Azzollini J, Manoukian S, Radice P, Peterlongo P (2018). Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction. Frontiers in oncology, 8(), 480. . PMID: 30410870.
23.) Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, Domchek SM, Robson M, Spurdle AB, Ramus SJ, Mavaddat N, Terry MB, Neuhausen SL, Schmutzler RK, Simard J, Pharoah PDP, Offit K, Couch FJ, Chenevix-Trench G, Easton DF, Antoniou AC (2017 Jul 1). Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 109(7), . . PMID: 28376175.
24.) Catucci I, Casadei S, Ding YC, Volorio S, Ficarazzi F, Falanga A, Marchetti M, Tondini C, Franchi M, Adamson A, Mandell J, Walsh T, Olopade OI, Manoukian S, Radice P, Ricker C, Weitzel J, King MC, Peterlongo P, Neuhausen SL (2016 Nov). Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast cancer research and treatment, 160(1), 121-129. . PMID: 27624329.
25.) Fackenthal JD, Yoshimatsu T, Zhang B, de Garibay GR, Colombo M, De Vecchi G, Ayoub SC, Lal K, Olopade OI, Vega A, Santamariña M, Blanco A, Wappenschmidt B, Becker A, Houdayer C, Walker LC, López-Perolio I, Thomassen M, Parsons M, Whiley P, Blok MJ, Brandão RD, Tserpelis D, Baralle D, Montalban G, Gutiérrez-Enríquez S, Díez O, Lazaro C, Spurdle AB, Radice P, de la Hoya M (2016 Aug). Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples. Journal of medical genetics, 53(8), 548-58. doi: 10.1136/jmedgenet-2015-103570. PMID: 27060066.
26.) Azzollini J, Scuvera G, Bruno E, Pasanisi P, Zaffaroni D, Calvello M, Pasini B, Ripamonti CB, Colombo M, Pensotti V, Radice P, Peissel B, Manoukian S (2016 Jul). Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study. European journal of internal medicine, 32(), 65-71. doi: 10.1016/j.ejim.2016.03.010. PMID: 27062684.
27.) Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H, Brenner H, Brinton L, Brooks-Wilson (2016 May). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic oncology, 141(2), 386-401. . PMID: 25940428.
28.) Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navr (2016 Feb 9). Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast cancer research : BCR, 18(1), 15. . PMID: 26857456.
29.) Silvestri V, Rizzolo P, Scarnò M, Chillemi G, Navazio AS, Valentini V, Zelli V, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Pensotti V, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D, Ottini L (2015 Nov). Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy. European journal of cancer (Oxford, England : 1990), 51(16), 2289-95. doi: 10.1016/j.ejca.2015.07.020. PMID: 26248686.
30.) Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, Marin M, Damiola F, Bernard L, Pensotti V, Volorio S, Dall'Olio V, Meindl A, Bartram C, Sutter C, Surowy H, Sornin V, Dondon MG, Eon-Marchais S, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM, Mitchell G, James PA, Thompson E, Marchetti M, Verzeroli C, Tartari C, Capone GL, Putignano AL, Genuardi M, Medici V, Marchi I, Federico M, Tognazzo S, Matricardi L, Agata S, Dolcetti R, Della Puppa L, Cini G, Gismondi V, Viassolo V, Perfumo (2015 Sep 15). FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human molecular genetics, 24(18), 5345-55. . PMID: 26130695.
31.) Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, Johnson N, Ghoussaini M, Hopper JL, Southey MC, Apicella C, Stone J, Schmidt MK, Broeks A, Van't Veer LJ, Hogervorst FB, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Gibson L, Aitken Z, Warren H, Sawyer E, Tomlinson I, Kerin MJ, Miller N, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Guénel P, Truong T, Cordina-Duverger E, Sanchez M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Benitez J, Zamora MP, Arias Perez JI, Menéndez P, (2015 May 15). Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human molecular genetics, 24(10), 2966-84. . PMID: 25652398.
32.) Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, Wang Q, Dennis J, Dunning AM, Shah M, Luben R, Brown J, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Czene K, Darabi H, Eriksson M, Peto J, Dos-Santos-Silva I, Dudbridge F, Johnson N, Schmidt MK, Broeks A, Verhoef S, Rutgers EJ, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Couch FJ, Olson JE, Vachon C, Pankratz VS, Lambrechts D, Wildiers H, Van Ongeval C, van Limbergen E, Kr (2015 May). Prediction of breast cancer risk based on profiling with common genetic variants. Journal of the National Cancer Institute, 107(5), . . PMID: 25855707.
33.) Guo Q, Schmidt MK, Kraft P, Canisius S, Chen C, Khan S, Tyrer J, Bolla MK, Wang Q, Dennis J, Michailidou K, Lush M, Kar S, Beesley J, Dunning AM, Shah M, Czene K, Darabi H, Eriksson M, Lambrechts D, Weltens C, Leunen K, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Blomqvist C, Aittomäki K, Fagerholm R, Muranen TA, Couch FJ, Olson JE, Vachon C, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Broeks A, Hogervorst FB, Haiman CA, Henderson (2015 May). Identification of novel genetic markers of breast cancer survival. Journal of the National Cancer Institute, 107(5), . . PMID: 25890600.
34.) Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlertsen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Conejero RA, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini (2015 Apr 25). An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast cancer research : BCR, 17(1), 61. . PMID: 25925750.
35.) Pirie A, Guo Q, Kraft P, Canisius S, Eccles DM, Rahman N, Nevanlinna H, Chen C, Khan S, Tyrer J, Bolla MK, Wang Q, Dennis J, Michailidou K, Lush M, Dunning AM, Shah M, Czene K, Darabi H, Eriksson M, Lambrechts D, Weltens C, Leunen K, van Ongeval C, Nordestgaard BG, Nielsen SF, Flyger H, Rudolph A, Seibold P, Flesch-Janys D, Blomqvist C, Aittomäki K, Fagerholm R, Muranen TA, Olsen JE, Hallberg E, Vachon C, Knight JA, Glendon G, Mulligan AM, Broeks A, Cornelissen S, Haiman CA, Henderson BE, Schuma (2015 Apr 22). Common germline polymorphisms associated with breast cancer-specific survival. Breast cancer research : BCR, 17(1), 58. . PMID: 25897948.
36.) Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John E (2015 Apr 7). Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA, 313(13), 1347-61. . PMID: 25849179.
37.) Belloni E, Veronesi G, Rotta L, Volorio S, Sardella D, Bernard L, Pece S, Di Fiore PP, Fumagalli C, Barberis M, Spaggiari L, Pelicci PG, Riva L (2015 Apr). Whole exome sequencing identifies driver mutations in asymptomatic computed tomography-detected lung cancers with normal karyotype. Cancer genetics, 208(4), 152-5. doi: 10.1016/j.cancergen.2015.02.004. PMID: 25850996.
38.) Berrino J, Berrino F, Francisci S, Peissel B, Azzollini J, Pensotti V, Radice P, Pasanisi P, Manoukian S (2015 Mar). Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. Familial cancer, 14(1), 117-28. doi: 10.1007/s10689-014-9766-8. PMID: 25373702.
39.) Kabisch M, Lorenzo Bermejo J, Dünnebier T, Ying S, Michailidou K, Bolla MK, Wang Q, Dennis J, Shah M, Perkins BJ, Czene K, Darabi H, Eriksson M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Neven P, Peeters S, Weltens C, Couch FJ, Olson JE, Wang X, Purrington K, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, dos-Santos-Silva I, Johnson N, Fletcher O, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Schmidt MK, Broeks A, Cornelissen S, Hogervorst FB, Li J, Br (2015 Feb). Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 36(2), 256-71. . PMID: 25586992.
40.) Bodini M, Ronchini C, Giacò L, Russo A, Melloni GE, Luzi L, Sardella D, Volorio S, Hasan SK, Ottone T, Lavorgna S, Lo-Coco F, Candoni A, Fanin R, Toffoletti E, Iacobucci I, Martinelli G, Cignetti A, Tarella C, Bernard L, Pelicci PG, Riva L (2015 Jan 22). The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. Blood, 125(4), 600-5. . PMID: 25499761.
41.) Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S, Carlebur S, O'Reilly M, Betts JA, Hillman KM, Kaufmann S, Beesley J, Canisius S, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Schmidt MK, Broeks A, Hogervorst FB, van der Schoot CE, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching PA, Ruebner M, Ekici AB, Beckmann MW, Peto J, dos-Santos-Silva I, Fletcher O, Johnson N, Pharoah PD, Bolla MK, Wang Q, Dennis J, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Burwink (2015 Jan 8). Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. American journal of human genetics, 96(1), 5-20. . PMID: 25529635.
42.) Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gómez Garcia EB, Olopade OI, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Karlan BY, Orsulic S, Lester J, Chung WK, Miron A, Southey MC, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Ding YC, Neu (2015 Jan). Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 24(1), 308-16. . PMID: 25336561.
43.) La Verde N, Corsi F, Moretti A, Peissel B, Dalu D, Girelli S, Fasola C, Gambaro A, Roversi G, Azzollini J, Radice P, Pensotti V, Farina G, Manoukian S (2016 Jan-Feb). A targeted approach to genetic counseling in breast cancer patients: the experience of an Italian local project. Tumori, 102(1), 45-50. doi: 10.5301/tj.5000407. PMID: 26357973.
Cogentech's CGTlab is offering its diagnostic services for Hereditary Tumors (Cancer Risk) and for Personalized Medicine (Therapy) to clinicians, laboratories and hospitals.
